Eli Lilly and (NYSE:LLY) Given New $356.00 Price Target at Mizuho

Eli Lilly and (NYSE:LLYGet Rating) had its price objective lifted by Mizuho from $315.00 to $356.00 in a research report released on Monday morning, The Fly reports.

Several other research firms also recently weighed in on LLY. DZ Bank upgraded shares of Eli Lilly and from a hold rating to a buy rating and set a $291.00 price target for the company in a research report on Friday, January 21st. Daiwa Capital Markets initiated coverage on shares of Eli Lilly and in a research report on Thursday, March 10th. They set an outperform rating and a $286.00 price target for the company. Morgan Stanley increased their price objective on shares of Eli Lilly and from $364.00 to $369.00 in a report on Friday. Bank of America increased their price objective on shares of Eli Lilly and from $300.00 to $315.00 in a report on Thursday, March 17th. Finally, Wells Fargo & Company increased their price objective on shares of Eli Lilly and from $280.00 to $305.00 in a report on Friday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus price target of $302.56.

LLY opened at $289.56 on Monday. Eli Lilly and has a twelve month low of $182.92 and a twelve month high of $314.00. The company has a quick ratio of 0.97, a current ratio of 1.23 and a debt-to-equity ratio of 1.68. The company has a 50-day moving average price of $282.26 and a 200 day moving average price of $263.70. The company has a market cap of $275.76 billion, a PE ratio of 42.90, a price-to-earnings-growth ratio of 2.31 and a beta of 0.43.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings results on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, topping the consensus estimate of $2.32 by $0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 102.32%. The firm had revenue of $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. During the same quarter in the prior year, the firm earned $1.87 EPS. The company’s revenue for the quarter was up 14.8% on a year-over-year basis. As a group, sell-side analysts expect that Eli Lilly and will post 8.41 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Monday, May 16th will be given a dividend of $0.98 per share. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.35%. Eli Lilly and’s payout ratio is currently 58.07%.

In related news, SVP Ilya Yuffa sold 1,000 shares of the stock in a transaction that occurred on Tuesday, February 15th. The shares were sold at an average price of $237.45, for a total transaction of $237,450.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction that occurred on Thursday, March 17th. The stock was sold at an average price of $283.80, for a total transaction of $62,436,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 1,088,551 shares of company stock valued at $307,943,730 in the last ninety days. 0.12% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the business. State Street Corp boosted its position in Eli Lilly and by 2.5% in the 4th quarter. State Street Corp now owns 33,929,864 shares of the company’s stock valued at $9,372,107,000 after buying an additional 813,983 shares during the period. Capital World Investors boosted its position in Eli Lilly and by 13.9% in the 4th quarter. Capital World Investors now owns 19,115,896 shares of the company’s stock valued at $5,280,206,000 after buying an additional 2,325,514 shares during the period. Geode Capital Management LLC raised its holdings in shares of Eli Lilly and by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 14,731,168 shares of the company’s stock valued at $4,059,130,000 after purchasing an additional 409,009 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Eli Lilly and by 10.7% in the 3rd quarter. Jennison Associates LLC now owns 9,864,516 shares of the company’s stock valued at $2,279,196,000 after purchasing an additional 953,521 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of Eli Lilly and in the 4th quarter valued at $2,213,765,000. 82.75% of the stock is owned by institutional investors.

About Eli Lilly and (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Stories

The Fly logo

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.